Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2020.10.15.340612: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Proteins were stained using primary antibodies against β-actin (1:10,000, AC-15, Sigma), strep II-tag (1:1,000, NBP2-43735, Novus), strep II-tag (1:2,000, ab76949, abcam), GAPDH (1:1,000, 607902, Biolegend), pSTAT1 (1:1,000, Y701, Cell Signaling Technology), STAT1 (1:1,000, 9172S, Cell Signaling Technology), pSTAT2 (1:1,000, Y690, Cell Signaling Technology), STAT2 (1:1,000, 4594S, Cell Signaling Technology), IFNAR1 (1:1,000, ab45172, abcam), p62 (1:1,000, … SciScore for 10.1101/2020.10.15.340612: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Proteins were stained using primary antibodies against β-actin (1:10,000, AC-15, Sigma), strep II-tag (1:1,000, NBP2-43735, Novus), strep II-tag (1:2,000, ab76949, abcam), GAPDH (1:1,000, 607902, Biolegend), pSTAT1 (1:1,000, Y701, Cell Signaling Technology), STAT1 (1:1,000, 9172S, Cell Signaling Technology), pSTAT2 (1:1,000, Y690, Cell Signaling Technology), STAT2 (1:1,000, 4594S, Cell Signaling Technology), IFNAR1 (1:1,000, ab45172, abcam), p62 (1:1,000, GP62-N, ProGen), LC3a/β (1:200 β-actinsuggested: (Sigma-Aldrich Cat# A5441, RRID:AB_476744)GAPDHsuggested: (BioLegend Cat# 607902, RRID:AB_2734503)pSTAT1suggested: (Fluidigm Cat# 3153003, RRID:AB_2661824)Y701 , Cell Signaling Technology) , STAT1suggested: None9172S , Cell Signaling Technology) , pSTAT2 ( 1:1,000 , Y690 , Cell Signaling Technology) , STAT2suggested: NoneIFNAR1suggested: (Abcam Cat# ab45172, RRID:AB_775764)p62suggested: (Progen Cat# GP62-N, RRID:AB_2801426)GP62-Nsuggested: (Progen Cat# GP62-N, RRID:AB_2801426)LC3a/βsuggested: None, M2, Sigma), V5-tag (1:1,000, D3H8Q, Cell Signaling Technology), SARS-CoV-2 (COVID-19) spike antibody (1:1000, 1A9, Biozol), SARS-CoV/SARS-CoV-2 V5-tagsuggested: (Cell Signaling Technology Cat# 13202, RRID:AB_2687461)The cells were stained using primary antibodies against strep II-tag (1:200, NBP2-43735, Novus) and TGN46 (1:400, AHP500GT, Bio Rad), secondary antibodies fluorescently labelled with AlexaFluor568 targeting rabbit-IgGs (1:400, A10042, Invitrogen) and AlexaFluor647 targeting sheep-IgG (1:400, A21448, Invitrogen), and DAPI (1:1,000) to stain nuclei. NBP2-43735suggested: NoneTGN46suggested: (Bio-Rad Cat# AHP500GT, RRID:AB_2203291)A10042suggested: (Thermo Fisher Scientific Cat# A10042, RRID:AB_2534017)AlexaFluor647 targeting sheep-IgGsuggested: NoneA21448suggested: NoneExperimental Models: Cell Lines Sentences Resources Cell lines and cell culture and viruses: HEK293T cells were purchased from American type culture collection (ATCC: #CRL3216). HEK293Tsuggested: ATCC Cat# CRL-3216, RRID:CVCL_0063)Generation of stable THP-1 cells: THP-1 cell liens were generated by transduction with lentivirus generated with the indicated pLVX-EF1alpha vectors (kind gift from Nevan Krogan), as well as packaging vectors psPax2 and pMD2. THP-1suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)Immunofluorescence: HeLa GL cells were transfected using TransIT-LT1 and grown on coverslips in 24-well plates. HeLa GLsuggested: NoneInhibition of SARS-CoV-2 by immune modulation: 300,000 Calu-3 cells were seeded in 12-well plates. Calu-3suggested: NoneThe viruses were propagated by infecting 70% confluent Vero E6 in 75 cm2 cell culture flasks at a MOI of 0.003 in 3.5 ml serum-free medium containing 1 μg/ml trypsin. Vero E6suggested: NoneProteome analysis: For the proteome analysis of infected cells, 0.6×106 Caco-2 cells were infected with SARS-CoV-2 BetaCoV/Netherlands/01/NL/2020 at an MOI of 0.5 and harvested 24 h and 48 h post infection with TM lysis buffer supplemented with 1:500 protease inhibitor. Caco-2suggested: NoneSoftware and Algorithms Sentences Resources Images were acquired using a Zeiss LSM710 and analyzed with Fiji ImageJ. Fijisuggested: (Fiji, RRID:SCR_002285)ImageJsuggested: (ImageJ, RRID:SCR_003070)The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD021899. PRIDEsuggested: (Pride-asap, RRID:SCR_012052)MaxQuant 1.6.15.0 was used to identify proteins and quantify by LFQ with the following parameters: Database, Uniprot_AUP000005640_Hsapiens_20200120.fasta supplemented with the sequences of NSP1_V5, NSP7_V5, NSP15_V5, NSP16_V5, E_V5, M_V5, N_V5, S_V5, ORF3_V5, ORF6_V5, ORF7_V5 and Spike protein from SARSCoV239; MS tol, 10ppm; MS/MS tol, 20ppm MaxQuantsuggested: (MaxQuant, RRID:SCR_014485)GO Analysis: From the proteome of the respective samples, proteins regulated more than 4-fold compared to the vector control were extracted and submitted to PANTHER (cellular component analysis). PANTHERsuggested: (PANTHER, RRID:SCR_004869)We used MATLAB 2019b for the half-life analysis. MATLABsuggested: (MATLAB, RRID:SCR_001622)Statistical analysis: Statistical analyses were performed using GraphPad PRISM 8 (GraphPad Software). GraphPad PRISMsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-